Avalyn Pharma (NASDAQ:AVLN) Sets New 1-Year Low - Here's What Happened

Key Points

• Avalyn Pharma shares hit a new 52-week low, falling to $23.08 before recovering slightly to $23.74, compared with a prior close of $24.80.
• Analyst sentiment remains generally positive, with an average “Moderate Buy” rating and a $60 price target, although some firms issued sell ratings.
• The clinical-stage biotech reported a quarterly loss of $0.98 per share, narrowly beating estimates, while institutional investors—including Montanova Capital and Braidwell—established significant new positions.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday. The stock traded as low as $23.08 and last traded at $23.74, with a volume of 403,934 shares. The stock had previously closed at $24.80.

Analyst Ratings Changes

AVLN has been the subject of a number of research analyst reports. Morgan Stanley increased their target price on Avalyn Pharma from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Raymond James Financial assumed coverage on Avalyn Pharma in a research note on Friday, October 2nd. They issued an "outperform" rating and a $60.00 price target on the stock. Weiss Ratings initiated coverage on Avalyn Pharma in a research report on Thursday, August 13th. They set a "sell (d+)" rating for the company. Finally, Wall Street Zen downgraded Avalyn Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, September 20th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $60.00.

Avalyn Pharma Price Performance

The firm has a market capitalization of $1.05 billion and a PE ratio of -1.04. The firm has a 50 day moving average price of $33.04. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating analysts' consensus estimates of ($1.03) by $0.05. Analysts forecast that Avalyn Pharma Inc. will post -3.86 earnings per share for the current year.

Institutional Investors Weigh In On Avalyn Pharma

A number of hedge funds have recently modified their holdings of AVLN. Bank of New York Mellon Corp purchased a new stake in shares of Avalyn Pharma in the 2nd quarter valued at approximately $1,321,000. State Street Corp purchased a new position in shares of Avalyn Pharma during the 2nd quarter worth approximately $10,501,000. Braidwell LP purchased a new position in shares of Avalyn Pharma during the 2nd quarter worth approximately $26,382,000. Finally, Montanova Capital LLC acquired a new stake in Avalyn Pharma in the 2nd quarter valued at approximately $82,402,000.

About Avalyn Pharma

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company's primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn's lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company's development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.